5852-49-3

Basic information

• Product Name: 5-PHENYL-1,3,4-OXATHIAZOL-2-ONE
• Synonyms: 5-PHENYL-1,3,4-OXATHIAZOL-2-ONE
• CAS NO: 5852-49-3
• Molecular Formula: C₈H₅NO₂S
• Molecular Weight: 179.2
• Mol File: 5852-49-3.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-PHENYL-1,3,4-OXATHIAZOL-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PHENYL-1,3,4-OXATHIAZOL-2-ONE(5852-49-3)
• EPA Substance Registry System: 5-PHENYL-1,3,4-OXATHIAZOL-2-ONE(5852-49-3)

Safety Data

• Hazardous Substances Data: 5852-49-3(Hazardous Substances Data)

Usage

General Description

5-Phenyl-1,3,4-oxathiazol-2-one is a chemical compound with the molecular formula C9H5NOS2. This organic compound falls under the category of organosulfur compounds, which contain carbon-sulfur bonds, and more specifically, 1,3,4-oxathiazoles, characterized by a five-member heterocyclic ring. The structure also includes a phenyl group, a functional group characterized by a ring of six carbon atoms. Potential applications for this type of compound can range from use in chemical synthesis, pharmaceuticals, and materials science, but specific use or properties of 5-Phenyl-1,3,4-oxathiazol-2-one are not widely documented in scientific literature. Final properties and applications would likely depend on further reactions to create derivatives of this base compound.

Upstream product

• 28059-36-1 N-benzoyltrichloromethanesulfenamide 
• 1821-34-7 N-chlorobenzamide 
• 55-21-0 benzamide 
• 7440-44-0 pyrographite 
• 594-42-3 chlorothio-trichloro-methane 
• 2757-23-5 chloro(chlorosulfanyl)methanone 

Downstream Products

• 64621-31-4 N-benzoyl-S-(morpholine-4-carbonyl)-thiohydroxylamine 
• 73501-00-5 5-phenyl-2-trichloromethyl-1,3,4-oxathiazole 
• 4115-15-5 3,5-diphenyl-[1,2,4]thiadiazole 
• 50483-74-4 3-phenyl-5-(p-tolyl)-1,2,4-thiadiazole 
• 100-47-0 benzonitrile 
• 76010-55-4 methyl 2-(3-phenyl-1,2,4-thiadiazol-5-yl)benzoate 
• 10514-34-8 3-phenylisothiazole 
• 2362-05-2 benzonitrile sulphide 
• 21634-42-4 dibenzo[b,i]thianthrene-5,7,12,14-tetraone 
• 80-73-9 1,3-dimethyl-2-imidazolidinone 
• 76010-61-2 2-(3-phenyl-1,2,4-thiadiazol-5-yl)benzonitrile 
• 120587-93-1 3,5-Diphenyl-[1,2,4]thiazaphosphole 
• 120587-96-4 3,4,5-Triphenyl-[1,2]thiaphosphole 
• 120587-95-3 3,5-Diphenyl-[1,2,4]thiadiphosphole 

Relevant articles and documents

Discovery of a novel, isothiazolonaphthoquinone-based small molecule activator of FOXO nuclear-cytoplasmic shuttling

FOXO factors are tumour suppressor proteins commonly inactivated in human tumours by posttranslational modifications. Furthermore, genetic variation within the FOXO3a gene is consistently associated with human longevity. Therefore, the pharmacological activation of FOXO proteins is considered as an attractive therapeutic approach to treat cancer and agerelated diseases. In order to identify agents capable of activating FOXOs, we tested a collection of small chemical compounds using image-based high content screening technology. Here, we report the discovery of LOM612 (compound 1a), a newly synthesized isothiazolonaphthoquinone as a potent FOXO relocator. Compound 1a induces nuclear translocation of a FOXO3a reporter protein as well as endogenous FOXO3a and FOXO1 in U2OS cells in a dose-dependent manner. This activity does not affect the subcellular localization of other cellular proteins including NFkB or inhibit CRM1-mediated nuclear export. Furthermore, compound 1a shows a potent antiproliferative effect in human cancer cell lines.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes

We have discovered a novel series of isothiazole-based phenylpropanoic acids as GPR120 agonists. Extensive structure-activity relationship studies led to the discovery of a potent GPR120 agonist 4x, which displayed good EC50 values in both calcium and β-arrestin assays. It also presented good pharmaceutical properties and a favorable PK profile. Moreover, it demonstrated in vivo antidiabetic activity in C57BL/6 DIO mice. Studies in WT and knockout DIO mice showed that it improved glucose handling during an OGTT via GPR120. Overall, 4x possessed promising antidiabetic effect and good safety profile to be a development candidate.